19 October 2020 - - US-based portable, clinical-grade laboratory developer SG Blocks, Inc. (NASDAQ: SGBX) and South Korean diagnostic tests and equipment maker OSANG Healthcare Co., Ltd have inked a Managed Supply Agreement building on their distributorship agreement executed earlier this year, to distribute OHC's "GeneFinder COVID-19 Plus RealAmp Kit" test in the United States and Canada, the companies said.

It is expected that the partnership will enable a much more efficient supply-chain arrangement for OSANG tests, not just for SG Blocks customers but also as a regional distribution hub for pre-existing OSANG customers, including FEMA and large lab and hospital networks, significantly reducing the costs and delivery times.

OHC's test is designed to detect SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2), the virus that causes COVID-19, through a gene-based reverse transcription reaction and real-time polymerase chain reaction testing process that can provide 96 tests results in just over two hours, making it ideally suited to emergency, pop-up and point of care situations.

SG Blocks will have sales, marketing and distribution rights to OHC's product in the United States and Canada, and plans to leverage its customer base and relationships with federal government and state-level customers in particular who are only beginning to roll-out widespread SARS-CoV-2 testing centers.

SG Blocks is an innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction.

Each project starts with GreenSteel, the structural core and shell of an SG Blocks building, and then customized to client specifications.

OSANG Healthcare is a South Korea based global manufacturer and distributor of medical devices and in-vitro diagnostics solutions.

Devoted since inception to the development of diagnostic biosensors for blood glucose measurement, OSANG Healthcare envisions medical devices becoming as commonplace as home appliances, easily measuring all diseases across the globe as "Technology for Human."

OSANG Healthcare currently exports its diagnostic biosensors for blood glucose, HbA1c and cholesterol to more than 110 countries, in its drive to become the leading researcher and developer of diagnostic sensors for heart disease and cancer, and of remote diagnosis systems.